Pharmacokinetics and safety of caspofungin in older infants and toddlers

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 4, 2009, Pages 1450-1456

  Neely, Michael ^a   Jafri, Hasan S ^b   Seibel, Nita ^c   Knapp, Katherine ^d   Adamson, Peter C ^e   Bradshaw, Susan K ^f   Strohmaier, Kim M ^f   Sun, Peng ^f   Bi, Sheng ^f   Dockendorf, Marissa Fallon ^f   Stone, Julie A ^f   Kartsonis, Nicholas A ^f  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; GLUCOSE BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFANT; MALE; MYCOSIS; NEUTROPENIA; OPTIMAL DRUG DOSE; PLASMA HALF LIFE; PRESCHOOL CHILD; PRIORITY JOURNAL; RESPIRATORY DISTRESS; SIDE EFFECT; TACHYPNEA; URIC ACID BLOOD LEVEL;

ANTIFUNGAL AGENTS; AREA UNDER CURVE; ECHINOCANDINS; FEMALE; HUMANS; INFANT; MALE;

EID: 65649126820     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01027-08     Document Type: Article

References (24)

1. Abelson, J. A., T. Moore, D. Bruckner, J. Deville, and K. Nielsen. 2005. Frequency of fungemia in hospitalized pediatric inpatients over 11 years at a tertiary care institution. Pediatrics 116:61-67.
2. Arathoon, E. G., E. Gotuzzo, L. M. Noriega, R. S. Berman, M. J. DiNubile, and C. A. Sable. 2002. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob. Agents Chemother. 46:451-457. (Pubitemid 34087195)
3. Ascioglu, S., J. H. Rex, B. de Pauw, J. E. Bennett, J. Bille, F. Crokaert, D. W. Denning, J. P. Donnelly, J. E. Edwards, Z. Erjavec, D. Fiere, O. Lortholary, J. Maertens, J. F. Meis, T. F. Patterson, J. Ritter, D. Selleslag, P. M. Shah, D. A. Stevens, and T. J. Walsh. 2002. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin. Infect. Dis. 34:7-14. (Pubitemid 33152659)
4. Bi, S., M. S. Schwartz, R. B. Desai, A. R. Miller, and B. K. Matuszewski. 2005. A semi-automated procedure for the determination of caspofungin in human plasma using solid-phase extraction and HPLC with fluorescence detection using secondary ionic interactions to obtain a highly purified extract. J. Liq. Chromatogr. Related Technol. 28:2895-2908. (Pubitemid 41609575)
5. Chanock, S. J., and T. J. Walsh. 1996. Evolving concepts of prevention and treatment of invasive fungal infections in pediatric bone marrow transplant recipients. Bone Marrow Transplant. 18(Suppl. 3):S15-S20. (Pubitemid 27026225)
6. Comely, O., M. Lasso, R. Betts, N. Klimko, J. Vazquez, G. Dobb, J. Velez, A. Williams-Diaz, J. Lipka, A. Taylor, C. Sable, and N. Kartsonis. 2007. Caspofungin for the treatment of less common forms of invasive candidiasis. J. Antimicrob. Chemother. 60:363-369. (Pubitemid 47243887)
7. De Pauw, B., T. J. Walsh, J. P. Donnelly, D. A. Stevens, J. E. Edwards, T. Calandra, P. G. Pappas, J. Maertens, O. Lortholary, C. A. Kaufman, D. W. Denning, T. F. Patterson, G. Maschmeyer, J. Bille, W. E. Dismukes, R. Herbrecht, W. W. Hope, C. C. Kibbler, B. J. Kullberg, K. A. Man-, P. Munoz, F. C. Odds, J. R. Perfect, A. Restrepo, M. Ruhnke, B. H. Segal, J. D. Sobel, T. C. Sorrell, C. Viscoli, J. R. Wingard, T. Zaoutis, and J. E. Bennett. 2008. Revised definitions of invasive fungal disease from the European Organiza-tion for Research and Treatment of Cancer/Invasive Fungal Infections Co-operative Group and the National Institute of Allergy and Infectious Dis-eases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 46:1813-1821.
8. DiNubile, M. J., R. J. Lupinacci, R. S. Berman, and C. A. Sable. 2002. Response and relapse rates of candidal esophagitis in HIV-infected patients treated with caspofungin. AIDS Res. Hum. Retrovir. 18:903-908.
9. Edmond, M. B., S. E. Wallace, D. K. McClish, M. A. Pfaller, R N. Jones, and R. P. Wenzel. 1999. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin. Infect. Dis. 29:239-244. (Pubitemid 29380177)
10. Engelhard, D. 1998. Bacterial and fungal infections in children undergoing bone marrow transplantation. Bone Marrow Transplant. 21(Suppl. 2):S78-S80. (Pubitemid 28223363)
11. Jarvis, W. R. 1995. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin. Infect. Dis. 20:1526-1530.
12. Maertens, J., I. Raad, G. Petrikkos, M. Boogaerts, D. Selleslag, F. B. Petersen, C. A. Sable, N. A. Kartsonis, A. Ngai, A. Taylor, T. F. Patterson, D. W. Denning, and T. J. Walsh. 2004. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis. 39:1563-1571. (Pubitemid 39578526)
13. Maertens, J., L. Madero, A. Reilly, T. Lehrnbecher, A. Groll, H. Jafri, M. Green, J. Nania, M. Bourque, B. Wise, A. Taylor, N. Kartsonis, J. Chow, C. Arndt, B. dePauw, and T. Walsh. 2007. A randomized, double-blind, multi-center trial of caspofungin (CAS) versus liposomal amphotericin B (LAMB) for empirical antifungal therapy (EAFRx) of pediatric patients with persis-tent fever and neutropenia (PFN). Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., abstr. M-621.
14. Mora-Duarte, J., R Betts, C. Rotstein, A. L. Colombo, L. Thompson-Moya, J. Smietana, R. Lupinacci, C. Sable, N. Kartsonis, and J. Perfect. 2002. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347:2020-2029. (Pubitemid 35461658)
15. Saez-Llorens, X., M. Macias, P. Maiya, J. Pineros, H. S. Jafri, A. Chatterjee, G. Ruiz, J. Raghavan, S. K. Bradshaw, N. A. Kartsonis, P. Sun, K. M. Strohmaier, M. Fallon, S. Bi, J. A. Stone, and J. Chow. 2009. Pharmacoki-netics and safety of caspofungin in neonates and infants less than 3 months of age. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. 53:869-875.
16. Sandhu, P., W. Lee, X. Xu, B. F. Leake, M. Yamazaki, J. A. Stone, J. H. Lin, P. G. Pearson, and R. B. Kim. 2005. Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab. Dispos. 33:676-682. (Pubitemid 40593883)
17. Steinbach, W., and T. J. Walsh. 2006. Mycoses in pediatric patients. Infect. Dis. Clin. N. Am. 20:663-678. (Pubitemid 44389928)
18. Stone, J., E. Migoya, S. Li, P. Deutsch, G. Winchell, and K. Ghosh. 2002. Safety and pharmacokinetics of higher doses of caspofungin. 42nd Intersci. Conf. Antimicrob. Agents Chemother., abstr. 1389. (Pubitemid 34157659)
19. Villaneuva, A., E. G. Arathoon, E. Gotuzzo, R. S. Berman, M. J. DiNubile, and C. A. Sable. 2001. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin. Infect. Dis. 33:1529-1535. (Pubitemid 34246147)
20. Villaneuva, A., E. Gotuzzo, E. G. Arathoon, L. M. Noriega, N. A. Kartsonis, R J. Lupinacci, J. M. Smietana, M. J. DiNubile, and C. A. Sable. 2002. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am. J. Med. 113:294-299. (Pubitemid 35287295)
21. Walsh, T. J., C. Gonzalez, C. A. Lyman, S. J. Chanock, and A. Pizzo. 1996. Invasive fungal infections in children: recent advances in diagnosis and treatment. Adv. Pediatr. Infect. Dis. 11:187-290.
22. Walsh, T. J., H. Teppler, G. R. Donowitz, J. A. Maertens, L. R. Baden, A. Dmoszynska, O. A. Comely, M. R Bourque, R J. Lupinacci, C. A. Sable, and B. E. dePauw. 2004. Caspofungin versus liposomal amphotericin B for em-pirical antifungal therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. 351:1391-1402. (Pubitemid 38656859)
23. Walsh, T. J., P. C. Adamson, N. L. Seibel, P. M. Flynn, M. N. Neely, C. Schwartz, A. Shad, S. L. Kaplan, M. M. Roden, J. A. Stone, A. Miller, S. K. Bradshaw, S. X. Li, C. A. Sable, and N. A. Kartsonis. 2005. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob. Agents Chemother. 49:4536-4545. (Pubitemid 41552583)
24. Zaoutis, T. E., H. S. Jafri, L.-M. Huang, F. Locatelli, A. Barzilai, W. Ebell, W. J. Steinbach, J. Bradley, J. M. Lieberman, C-C. Hsiao, N. Siebel, H. Laws, M. Gamba, M. Petrecz, A. F. Taylor, K. M. Strohmaier, J. W. Chow, N. A. Kartsonis, and A. L. Ngai. A prospective, multicenter study of caspo-fungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. Pediatrics, in press.